Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7475113 | 0.89 | — | — | |
| SCHEMBL8844986 | 0.86 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL8845010 | 0.85 | — | — | |
| SCHEMBL8844131 | 0.85 | — | — | |
| SCHEMBL8844216 | 0.82 | — | — | |
| SCHEMBL7471175 | 0.82 | — | — | |
| SCHEMBL8844143 | 0.82 | — | — | |
| SCHEMBL7902272 | 0.81 | KDM4E (0.32) | — | |
| SCHEMBL8844255 | 0.79 | ADRA2A (0.30) | ADRA2AADRA2BADRA2C | |
| SCHEMBL7902304 | 0.77 | ADRA2A (0.35) | SIGMAR1ADRA2AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6201119-B1 | 2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPIN-9-AMINE COMPOUNDS USEFUL AS INTERMEDIATES TO ANTIVIRALS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-03-13 | — | — | US | disclosed |
| EP-0605499-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO 4,5,1-jk] 1,4]-BENZODIAZEPIN-2(1H -)-THIONES | JANSSEN PHARMACEUTICA NV (BE) | 1997-11-12 | — | — | EP | disclosed |
| CN-1034122-C | Antiviral tetrahydroimioazo [1,4] benzodiazepin-2-(thi) ones | JANSSEN PHARMACEUTICA NV (BE) | 1997-02-26 | — | — | CN | disclosed |
| US-5599982-A | Process for preparing enantiomerically pure imidazo[4,5,1-JK][1,4]-benzodiazepin-2(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-02-04 | — | — | US | disclosed |
| US-5543570-A | Intermediates for preparing enantiomerically pure imidazo[4,5,1-JK][1,4]-benzodiazepin-2-(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-08-06 | — | — | US | disclosed |
| US-5463049-A | Process for preparing enantiomerically pure imidazo[4,5,1-JK][1,4]-benzodiazepin-2(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-10-31 | — | — | US | disclosed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | disclosed |
| EP-0605499-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO 4,5,1-jk] 1,4]-BENZODIAZEPIN-2(1H -)-THIONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-07-13 | — | — | EP | disclosed |
| US-5270464-A | Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-14 | — | — | US | disclosed |
| WO-1993006106-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE IMIDAZO[4,5,1-jk][1,4]-BENZODIAZEPIN-2(1H^_)-THIONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-01 | — | — | WO | disclosed |
| EP-0534539-A1 | Process for preparing enantiomerically pure imidazo[4,5,1-jk]-[1,4]-benzodiazepin-2(1H)-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-31 | — | — | EP | disclosed |